UB Paderborn / Katalog / Suche / in CDI

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)

European journal of clinical microbiology & infectious diseases, 2023-04, Vol.42 (4), p.453-459

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Antimicrobial agents and chemotherapy, 2023-04, Vol.67 (4), p.e0221321-e0221321

2023

Link zum Volltext

Verfügbarkeit prüfen

Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019

Antimicrobial agents and chemotherapy, 2022-01, Vol.66 (1), p.e0139721-e0139721

2022

Link zum Volltext

Verfügbarkeit prüfen

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017

Journal of global antimicrobial resistance., 2019-12, Vol.19, p.56-63

2019

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)

Antimicrobial agents and chemotherapy, 2019-03, Vol.63 (3)

2019

Link zum Volltext

Verfügbarkeit prüfen

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)

International journal of antimicrobial agents, 2018-06, Vol.51 (6), p.848-853

2018

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae

Antimicrobial agents and chemotherapy, 2015-03, Vol.59 (3), p.1478-1486

2015

Link zum Volltext

Verfügbarkeit prüfen

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)

European journal of clinical microbiology & infectious diseases, 2022-05, Vol.41 (5), p.867-873

2022

Link zum Volltext

Verfügbarkeit prüfen

Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design

Diagnostic microbiology and infectious disease, 2017-06, Vol.88 (2), p.198-200

2017

Link zum Volltext

Verfügbarkeit prüfen

Plain language summary: Does a person's age affect how common fungal infections are and how well drugs can kill the infections?

Future microbiology, 2022-07, Vol.17 (11), p.823-827

2022

Link zum Volltext

Verfügbarkeit prüfen

Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam

Journal of clinical microbiology, 2019-08, Vol.57 (8)

2019

Link zum Volltext

Verfügbarkeit prüfen

Ceftazidime–Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011–2015)

The Pediatric infectious disease journal, 2018-06, Vol.37 (6), p.549-554

2018

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates

Antimicrobial agents and chemotherapy, 2020-04, Vol.64 (5)

2020

Link zum Volltext

Verfügbarkeit prüfen

Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms

Diagnostic microbiology and infectious disease, 2020-07, Vol.97 (3), p.115054-115054, Article 115054

2020

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014

Antimicrobial agents and chemotherapy, 2016-04, Vol.60 (4), p.2537-2541

2016

Link zum Volltext

Verfügbarkeit prüfen

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin

Journal of clinical microbiology, 2019-09, Vol.57 (9)

2019

Link zum Volltext

Verfügbarkeit prüfen

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria

Antimicrobial agents and chemotherapy, 2015-01, Vol.59 (1), p.467-474

2015

Link zum Volltext

Verfügbarkeit prüfen

In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas

Antimicrobial agents and chemotherapy, 2015-06, Vol.59 (6), p.3627-3629

2015

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae

Antimicrobial agents and chemotherapy, 2014-12, Vol.58 (12), p.7595-7596

2014

Link zum Volltext

Verfügbarkeit prüfen

Determination of MIC and disk diffusion quality control guidelines for meropenem–vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination

Diagnostic microbiology and infectious disease, 2018-04, Vol.90 (4), p.324-328

2018

Link zum Volltext

Verfügbarkeit prüfen

Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin

Journal of clinical microbiology, 2017-10, Vol.55 (10), p.3130-3134

2017

Link zum Volltext

Verfügbarkeit prüfen

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV

Bioorganic & medicinal chemistry letters, 2017-08, Vol.27 (15), p.3353-3358

2017

Link zum Volltext

Verfügbarkeit prüfen

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes

International journal of antimicrobial agents, 2014-12, Vol.44 (6), p.552-556

2014

Link zum Volltext

Verfügbarkeit prüfen

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

Journal of clinical microbiology, 2018-06, Vol.56 (6)

2018

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017–2018)

Diagnostic microbiology and infectious disease, 2020-12, Vol.98 (4), p.115191-115191, Article 115191

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)

Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)

Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design

Plain language summary: Does a person's age affect how common fungal infections are and how well drugs can kill the infections?

Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam

Ceftazidime–Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011–2015)

In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates

Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms

In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria

In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae

Determination of MIC and disk diffusion quality control guidelines for meropenem–vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination

Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017–2018)

Suchergebnisse filtern